On April 28, 2026, Representatives Neal Dunn and Nanette Barragán reintroduced the Timely Access to Coverage Decisions Act (H.R. 8500), bipartisan legislation designed to reform and modernize the Medicare Local Coverage Determination (LCD) process.

The legislation reflects growing concerns across the healthcare industry regarding delays, inconsistencies, and limited transparency in how Medicare Administrative Contractors (MACs) evaluate coverage requests and LCD reconsiderations, particularly for innovative diagnostics, molecular testing, precision medicine, and emerging technologies.

For laboratories, providers, manufacturers, and patients, the proposal could represent a meaningful shift toward a more standardized and accountable Medicare coverage framework.

Why this matters

LCDs play a critical role in determining whether Medicare will cover specific tests, procedures, and services within a MAC’s jurisdiction. However, stakeholders have long voiced concerns regarding:

• Lengthy and inconsistent review timelines
• Lack of transparency in decision-making
• Limited stakeholder engagement
• Variability across MAC jurisdictions
• Challenges obtaining reconsideration of outdated policies
• Difficulty introducing emerging technologies into coverage pathways

These challenges are particularly impactful in rapidly evolving sectors such as molecular diagnostics, genomic testing, MRD testing, biomarker-driven oncology, and precision medicine, where evidence generation and clinical adoption often move faster than coverage policy updates.

According to the bill sponsors, Medicare beneficiaries frequently experience “unnecessary delays and administrative hurdles” due to inconsistent standards and insufficient transparency in the LCD process.

Key provisions of H.R. 8500

The proposed legislation would amend the Medicare LCD process by introducing several new requirements intended to improve timeliness, transparency, and stakeholder participation.

1. Defined timelines for LCD and reconsideration requests

The bill would establish clearer deadlines for MACs to review both formal LCD requests and reconsideration submissions.

Under the proposal:

• MACs would have 60 days to notify stakeholders if requests are incomplete
• Complete requests would require a decision within one year
• Similar timelines would apply to reconsideration requests

For stakeholders, this could create more predictability and accountability within the coverage development process.

2. Increased transparency requirements

The legislation would require MACs to publish:

• Supporting evidence
• Clinical rationale
• Draft policy information
• Public comments and responses

This could provide greater visibility into how coverage decisions are developed and allow stakeholders to better understand evidentiary expectations.

3. Expanded stakeholder engagement

The bill would mandate:

• Public meetings
• Formal written comment periods
• Opportunities for remote participation
• Expert clinical panel involvement for certain LCDs

This is particularly important for laboratories and manufacturers seeking to provide clinical evidence, real-world data, and operational insight during policy development.

4. Additional oversight for reconsideration decisions

The legislation also introduces a more formalized review process for certain LCD reconsideration determinations, creating additional procedural safeguards and accountability.

Potential impact on laboratories and diagnostic innovation

For the diagnostics industry, the legislation could have significant implications.

Laboratories developing innovative tests frequently encounter challenges when:

• Seeking coverage for emerging technologies
• Navigating inconsistent MAC policies
• Addressing outdated LCD language
• Requesting reconsideration of restrictive coverage criteria

The bill could help:

• Accelerate access to coverage pathways
• Improve visibility into evidentiary standards
• Reduce uncertainty during policy development
• Enhance consistency across jurisdictions
• Support more collaborative engagement between stakeholders and MACs

Organizations involved in molecular diagnostics, oncology, genetic testing, MRD testing, and precision medicine should closely monitor the bill’s progression.

Broader industry trends

The reintroduction of H.R. 8500 aligns with broader healthcare industry discussions surrounding:

• Prior authorization reform
• Timely access to care
• AI-driven utilization management
• Transparency in coverage decision-making
• Administrative simplification
• Regulatory modernization

As reimbursement complexity continues to increase, policymakers and industry stakeholders are placing greater emphasis on balancing evidence-based coverage with operational efficiency and patient access.

What stakeholders should do now

Healthcare organizations should consider:

• Monitoring legislative developments related to H.R. 8500
• Evaluating current LCD and reconsideration strategies
• Identifying policies that may warrant future reconsideration requests
• Strengthening clinical evidence and documentation processes
• Participating in industry advocacy efforts through organizations such as American Clinical Laboratory Association, Association for Molecular Pathology, and other specialty groups

As the policy landscape continues to evolve, proactive engagement and data-driven reimbursement strategies will remain critical for organizations navigating the Medicare coverage environment.

Reference

1. H.R.8500 - Timely Access to Coverage Decisions Act of 2026. Congress.gov. April 27, 2026. Accessed July 8, 2026. https://www.congress.gov/bill/119th-congress/house-bill/8500/text.